Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 10/20 | 0.58 |
| ▸ | CASP1 | P29466 | 4/20 | 0.56 |
| ▸ | CASP7 | P55210 | 7/20 | 0.54 |
| ▸ | CASP9 | P55211 | 3/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | CASP4 | P49662 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140616 | 0.92 | CASP3 (0.62) | CASP3CASP1CASP7CASP9ELANE | |
| SCHEMBL614741 | 0.92 | CASP3 (0.62) | CASP3CASP1CASP7CASP9ELANE | |
| SCHEMBL3692638 | 0.91 | CASP3 (0.58) | CASP3CASP1CASP7CASP9ELANE | |
| SCHEMBL7112627 | 0.91 | CASP3 (0.58) | CASP3CASP1CASP7CASP9ELANE | |
| SCHEMBL7364481 | 0.90 | CASP3 (0.62) | CASP3CASP1CASP7CASP9REN | |
| SCHEMBL17803368 | 0.90 | CASP3 (0.55) | CASP3CASP1CASP7CASP9ELANE | |
| SCHEMBL14070409 | 0.89 | CASP3 (0.56) | CASP3CASP1CASP7CASP9ELANE | |
| SCHEMBL24213871 | 0.89 | CASP3 (0.56) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL17494194 | 0.89 | CASP3 (0.56) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL7472606 | 0.89 | CASP3 (0.56) | CASP3CASP1CASP7CASP9ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363783-B1 | COMPOSITION FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ATOPIC DERMATITIS | INNOPHARMASCREEN INC (KR) | 2021-12-08 | — | — | EP | disclosed |
| CN-108137490-B | Composition for treating inflammatory bowel disease and atopic dermatitis | 创新药物筛选有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10278931-B2 | Composition for treatment of inflammatory bowel disease and atopic dermatitis | INNOPHARMASCREEN INC. (KR) | 2019-05-07 | — | — | US | disclosed |
| US-20180303774-A1 | COMPOSITION FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ATOPIC DERMATITIS | INNOPHARMASCREEN INC. (KR) | 2018-10-25 | — | — | US | disclosed |
| EP-3363783-A2 | COMPOSITION FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ATOPIC DERMATITIS | Innopharmascreen Inc. (KR) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017065495-A2 | COMPOSITION FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ATOPIC DERMATITIS | 주식회사 이노파마스크린 | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10278931-B2 | Composition for treatment of inflammatory bowel disease and atopic dermatitis | TSLP, CMA1, TPSG1 | CASP3 2083/4885CASP1 1566/4885CASP7 2108/4885 |
| US-20180303774-A1 | COMPOSITION FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ATOPIC DERMATITIS | TSLP, CMA1, TPSG1 | CASP3 2083/4885CASP1 1566/4885CASP7 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.